Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amlodipine folic acid with or without 5-methyltetrahydrofolate in hypertensive patients with MTHFR 677 TT genotype
ChiCTR2500099410Phase 4Recruiting
- Sponsor
- Peking University First Hospital
- Start
- Mar 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of amlodipine, folic acid and 5-MTHF in essential hypertension (2 arms), sponsored by Peking University First Hospital. Primary endpoint: Percentage reduction in plasma homocysteine from baseline after 8 weeks. Started Mar 2025; status: recruiting.
02
Drugs
amlodipinefolic acid5-MTHF
03
Conditions
essential hypertension
Beyond the preview
Go deeper on ChiCTR2500099410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500099410.